vs
Aligos Therapeutics, Inc.（ALGS）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
过去两年Aligos Therapeutics, Inc.的营收复合增速更高（-50.7% vs -100.0%）
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
ALGS vs RVMD — 直观对比
营收规模更大
ALGS
是对方的Infinity倍
$0
两年增速更快
ALGS
近两年复合增速
-100.0%
损益表 — Q4 2025 vs Q4 2024
| 指标 | | |
|---|---|---|
| 营收 | $169.0K | $0 |
| 净利润 | $-19.9M | $-194.6M |
| 毛利率 | — | — |
| 营业利润率 | -12907.7% | — |
| 净利率 | -11763.9% | — |
| 营收同比 | -72.1% | — |
| 净利润同比 | 75.8% | -20.4% |
| 每股收益（稀释后） | $4.23 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGSRVMD
| Q4 25 | $169.0K | — | ||
| Q3 25 | $741.0K | — | ||
| Q2 25 | $965.0K | — | ||
| Q1 25 | $311.0K | — | ||
| Q4 24 | $606.0K | $0 | ||
| Q3 24 | $1.3M | $0 | ||
| Q2 24 | $1.1M | $0 | ||
| Q1 24 | $694.0K | $0 |
净利润ALGSRVMD
| Q4 25 | $-19.9M | — | ||
| Q3 25 | $-31.5M | — | ||
| Q2 25 | $-15.9M | — | ||
| Q1 25 | $43.1M | — | ||
| Q4 24 | $-82.2M | $-194.6M | ||
| Q3 24 | $-19.3M | $-156.3M | ||
| Q2 24 | $5.1M | $-133.2M | ||
| Q1 24 | $-34.9M | $-116.0M |
营业利润率ALGSRVMD
| Q4 25 | -12907.7% | — | ||
| Q3 25 | -3827.4% | — | ||
| Q2 25 | -1924.0% | — | ||
| Q1 25 | -6187.5% | — | ||
| Q4 24 | -3393.2% | — | ||
| Q3 24 | -1610.5% | — | ||
| Q2 24 | -2489.5% | — | ||
| Q1 24 | -3176.7% | — |
净利率ALGSRVMD
| Q4 25 | -11763.9% | — | ||
| Q3 25 | -4256.0% | — | ||
| Q2 25 | -1643.8% | — | ||
| Q1 25 | 13854.7% | — | ||
| Q4 24 | -13556.1% | — | ||
| Q3 24 | -1540.7% | — | ||
| Q2 24 | 477.0% | — | ||
| Q1 24 | -5023.5% | — |
每股收益（稀释后）ALGSRVMD
| Q4 25 | $4.23 | — | ||
| Q3 25 | $-3.04 | — | ||
| Q2 25 | $-1.53 | — | ||
| Q1 25 | $-2.11 | — | ||
| Q4 24 | $-13.10 | $-1.13 | ||
| Q3 24 | $-3.07 | $-0.94 | ||
| Q2 24 | $0.81 | $-0.81 | ||
| Q1 24 | $-5.58 | $-0.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.8M | $2.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $53.5M | $2.3B |
| 总资产 | $88.5M | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALGSRVMD
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | — | ||
| Q2 25 | $122.9M | — | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | $2.3B | ||
| Q3 24 | $74.9M | $1.5B | ||
| Q2 24 | $94.5M | $1.6B | ||
| Q1 24 | $112.7M | $1.7B |
股东权益ALGSRVMD
| Q4 25 | $53.5M | — | ||
| Q3 25 | $71.8M | — | ||
| Q2 25 | $101.9M | — | ||
| Q1 25 | $116.4M | — | ||
| Q4 24 | $-29.0M | $2.3B | ||
| Q3 24 | $50.1M | $1.6B | ||
| Q2 24 | $67.2M | $1.6B | ||
| Q1 24 | $59.8M | $1.7B |
总资产ALGSRVMD
| Q4 25 | $88.5M | — | ||
| Q3 25 | $109.8M | — | ||
| Q2 25 | $134.7M | — | ||
| Q1 25 | $150.7M | — | ||
| Q4 24 | $70.1M | $2.6B | ||
| Q3 24 | $88.4M | $1.8B | ||
| Q2 24 | $108.8M | $1.8B | ||
| Q1 24 | $127.9M | $1.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-21.7M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-139.5M |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-567.7M |
8季度趋势，按日历期对齐
经营现金流ALGSRVMD
| Q4 25 | $-21.7M | — | ||
| Q3 25 | $-24.3M | — | ||
| Q2 25 | $-15.5M | — | ||
| Q1 25 | $-20.9M | — | ||
| Q4 24 | $-18.4M | $-138.3M | ||
| Q3 24 | $-20.1M | $-130.4M | ||
| Q2 24 | $-19.5M | $-128.2M | ||
| Q1 24 | $-22.7M | $-160.6M |
自由现金流ALGSRVMD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-139.5M | ||
| Q3 24 | — | $-133.9M | ||
| Q2 24 | — | $-130.6M | ||
| Q1 24 | — | $-163.7M |
现金转化率ALGSRVMD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
